NasdaqGM - Nasdaq Real Time Price USD

Sutro Biopharma, Inc. (STRO)

0.8480

+0.0237

+(2.88%)

At close: June 6 at 4:00:00 PM EDT

0.8500

+0.00

+(0.24%)

After hours: June 6 at 7:17:59 PM EDT

Sutro Biopharma Appoints Greg Chow as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Greg Chow as Chief Financial Officer (CFO), effective June 2, 2025. Mr. Chow brings over 25 years of executive leadership experience across corporate finance, capital markets, investment banking, financial accounting, and drug development operati

GlobeNewswire 5 days ago

STRO
+2.88%
Sutro Biopharma First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Sutro Biopharma ( NASDAQ:STRO ) First Quarter 2025 Results Key Financial Results Revenue: US$17.4m (up 34% from 1Q...

Simply Wall St. 28 days ago

STRO
+2.88%
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates

Sutro Biopharma (STRO) delivered earnings and revenue surprises of -44.44% and 25.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 30 days ago

STRO
+2.88%
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and PEGS, respectively - - Three INDs for wholly-owned programs anticipated in next 3 years, beginning with potential best-in-class Tissue Factor ADC, STRO-004, planned for 2H 2025 - - IND-enabling toxicology study ongoing for one program within A

GlobeNewswire 30 days ago

STRO
+2.88%
Sutro Biopharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences. Conference Details: The Citizens Life Sciences ConferenceDate: May 7-8, 2025Location: New York, NY BofA Securities 2025 Health Care ConferenceDate: May 13-15, 2025Location: Las Vegas, NV Webcasts

GlobeNewswire last month

STRO
+2.88%
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile -SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 in Chicago, IL. The presentations

GlobeNewswire last month

STRO
+2.88%
Reddit initiated, Netflix upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: MoffettNathanson upgraded Netflix (NFLX) to Buy from Neutral with a price target of $1,100, up from $850. The firm believes the company’s ability to monetize its engagement remains underappreciated. William Blair upgraded DocuSign (DOCU) to Outperform from Market Perform. The firm is bullish on the mar

TipRanks 2 months ago

EMR

NFLX

CION
Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Sutro Biopharma ( NASDAQ:STRO ) Full Year 2024 Results Key Financial Results Revenue: US$62.0m (down 60% from FY 2023...

Simply Wall St. 2 months ago

STRO
+2.88%
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

- The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater -SOUTH SAN FRANCISCO, Calif., March 15, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced expanded data in a late-breaking oral presentation from the dose-optimization portion of the REFRαME-

GlobeNewswire 2 months ago

STRO
+2.88%
Chipotle upgraded, Charter initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Loop Capital upgraded Chipotle (CMG) to Buy from Neutral with a price target of $65, up from $58. There is the potential for at least 7.0%-8.0% upside to the current consensus EPS estimate of $1.30 for 2025 if comparable sales continue to beat expectations over the course of the current year, the firm

TipRanks 2 months ago

AXP

CMG

DHR
Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler

Piper Sandler downgraded Sutro Biopharma (STRO) to Neutral from Overweight with a price target of $2, down from $8. The company is deprioritizing development of luvelta in order to focus resources on its early stage antibody-drug conjugates pipeline, the analyst tells investors in a research note. Piper downgraded Sutro after removing luvelta value. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by an

TipRanks 2 months ago

STRO
+2.88%
Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Strategic Focus and Financial ...

Sutro Biopharma Inc (STRO) extends its cash runway and strengthens partnerships while navigating workforce cuts and competitive challenges.

GuruFocus.com 2 months ago

STRO
+2.88%
Sutro Biopharma Falls as Company Cuts Workforce, Shifts Focus to ADCs

The company is cutting its workforce by nearly 50% as part of a strategic restructuring.

GuruFocus.com 2 months ago

STRO
+2.88%
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’

President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell and gene therapy pilot appeared to survive.

BioPharma Dive 2 months ago

SLRN

STRO
+2.88%

PLRX
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates

Sutro Biopharma (STRO) delivered earnings and revenue surprises of -3.49% and 34.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

STRO
+2.88%
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, with cash runway expected into at least Q4 2026, excluding anticipated milestones from existing collaborations – – Conference call today at 2:00 p.m. PT / 5:00 p.m. ET – SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIR

GlobeNewswire 2 months ago

STRO
+2.88%
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for wholly-owned programs expected in the next 3 years, beginning with novel Tissue Factor ADC, STRO-004, planned for 2H 2025 – – Jane Chung, President and COO, to succeed Bill Newell as CEO and Board Director – – Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, wi

GlobeNewswire 2 months ago

STRO
+2.88%
Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates

Oculis Holding AG (OCS) delivered earnings and revenue surprises of -58.33% and 98.78%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

STRO
+2.88%
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will present at the TD Cowen 45th Annual Health Care Conference taking place March 3-5, 2025 in Boston, MA. The presentation will be accessible through the News & Events page of the Investor Relations section of the company’s website

GlobeNewswire 3 months ago

STRO
+2.88%
We're Not Very Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 4 months ago

STRO
+2.88%

Performance Overview

Return	STRO	S&P 500 (^GSPC)
YTD	-53.91%	+2.02%
1-Year	-77.45%	+12.09%
3-Year	-80.90%	+45.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sutro Biopharma, Inc. (STRO)

Sutro Biopharma Appoints Greg Chow as Chief Financial Officer

Sutro Biopharma First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

Sutro Biopharma to Participate in Upcoming Investor Conferences

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

Reddit initiated, Netflix upgraded: Wall Street’s top analyst calls

Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Chipotle upgraded, Charter initiated: Wall Street’s top analyst calls

Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler

Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Strategic Focus and Financial ...

Sutro Biopharma Falls as Company Cuts Workforce, Shifts Focus to ADCs

Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’

Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

We're Not Very Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Rate

Performance Overview